Details for Patent: 5,616,346

US Patent 5,616,346: Scope, Claim Boundaries, and US Patent Landscape for Non-Aqueous Sodium Phosphate Colonic Purging Compositions

US 5,616,346 claims orally administrable, non-aqueous solid dosage forms (tablets and gelatin capsules) using sodium phosphate salts (monobasic, dibasic, and mixtures including tribasic) designed to disperse in the stomach to induce colonic purgation. The core claim boundary is not “sodium phosphate purgation” generally, but a specific formulation architecture: dry, non-aqueous dosage forms with defined salt concentration ranges and optional excipient classes (buffering, dispersal, binding) plus method constraints around administering the dry form without dispersing into water beforehand.

What does the patent claim, in one line?

A dry, non-aqueous oral sodium-phosphate colonic purgative formulation in tablet or gelatin capsule form, with defined salt compositions and optional buffering/dispersing/binding excipients, intended to disperse in the stomach and induce colon purgation, plus corresponding administration methods.

What is the claim scope in US 5,616,346?

1. Composition claims: sodium phosphate, non-aqueous dry dosage form, stomach dispersal

Independent claim 1 covers:

• Dosage form: “in a non-aqueous form selected from the group consisting of tablets and gelatin capsules”
• Active: “effective colonic purgative amount of at least one sodium phosphate salt”
• Disintegration/dispersal trigger: “capable of dispersal in the stomach”
• Optional excipients: “one or more additives selected from… buffering agents, dispersal agents and binding agents are optionally present”

Claim 19 further adds a numerical formulation envelope:

• Monobasic sodium phosphate: ~70 to 73%
• Dibasic sodium phosphate: ~26 to 30%
• Inert additives: ~1 to 4%
• Dosage forms: tablets or gelatin capsules
• Stomach dispersal and colonic purgation are maintained

Scope consequence: The patent is broad on salt identity (at least one sodium phosphate) in claim 1, but becomes narrow with specified concentration ranges and multi-salt recipes in dependent claims (2-5, 19).

2. Dependent composition claims: concentration windows and salt-specification variants

Key concentration/routing limitations:

• Claim 2: monobasic sodium phosphate only; 70 to 73 wt%
• Claim 3: dibasic sodium phosphate only; 26 to 30 wt%
• Claim 4: mixture monobasic (70 to 73 wt%) + dibasic (26 to 30 wt%)
• Claim 5: mixture of mono + di + tribasic sodium phosphate (tribasic allowed without concentration limits in claim 5)
• Claim 6-8: excipient selection from multiple “buffering agent” lists (claims differ by the disclosed set of members)

Notably, buffering agent examples appear in three separate dependent claim variants:

• Claim 6 (buffering agent group): magnesium hydroxide, aluminum hydroxide, calcium carbonate, magnesium carbonate
• Claim 7 (buffering agent group): anhydrous lactose, microcrystalline cellulose, AC-DI-SOL
• Claim 8 (buffering agent group): non-ionic detergents, mechanical adhesives, microcrystalline cellulose

Scope consequence: The excipient layer is structurally permissive in the independent claim (“one or more additives selected from buffering agents, dispersal agents and binding agents”), then becomes enumerated through dependent claims that can expand or constrain coverage depending on which excipient set a product uses.

3. Method claims: preparing non-aqueous mixture, dry administration without pre-dispersion, allowing purgation

Independent method claim 9 locks in a procedural posture:

1. Prepare: non-aqueous mixture “consisting essentially of at least one sodium phosphate salt”
2. Form dosage: orally administrable dry dosage form
3. Administer: “to a human without dispersing said dry dosage form into water prior to administration”
4. Allow effect: induce purgation

Dependent method claims then add:

• Claim 10: step (a) includes adding buffering agents, dispersal agents, and/or binders
• Claim 11: dosage form is gelatin capsules or tablets
• Claim 12: admixture includes monobasic + dibasic
• Claims 13-14: dosing rates by body weight for mono and di salts
• Claim 15: sodium phosphate is tribasic
• Claim 16: sodium phosphate is dibasic plus at least one of monobasic and tribasic
• Claim 17-18: a specific mammal method with explicit formulation percentages (~72% mono, ~26% di) and administration rate for dibasic (0.1 to 0.5 g/kg), plus repetition of administration step (c)

Scope consequence: Method infringement risk hinges on the “without dispersing into water prior to administration” limitation. It excludes regimens where the patient pre-disperses the dry solid into water before ingestion (if a competitor’s protocol follows that pattern).

How the independent claim 1 is likely to be interpreted (practical claim-boundary reading)

Key operative limitations in claim 1

• “Orally administrable”: solid oral delivery
• “non-aqueous”: no water-containing formulation as made/held by the composition as claimed
• “capable of dispersal in the stomach”: functional performance tied to in vivo stomach conditions
• “effective colonic purgative amount”: dosage must be in a purgative effective range
• “at least one sodium phosphate salt”: broad salt coverage
• “tablets and gelatin capsules”: dosage form boundary
• “consisting essentially of” via claim 9 step (a): method claim narrows excipient contamination conceptually, but claim 1 itself uses “consisting essentially” only indirectly through claim 9; still, claim 1’s excipient inclusion is limited to buffering/dispersal/binding categories

What claim 1 does not clearly cover

• Liquid formulations (since claim 1 is anchored to non-aqueous solid forms)
• Oral sodium phosphate purgatives that require reconstitution with water prior to administration (method claim 9 would not read cleanly; composition claim 1 could still be relevant if the product is non-aqueous solid)
• Dosage forms outside tablets/capsules (no sachets/powders as claimed)

Numerical claim content: “where the numbers matter”

Salt composition windows explicitly claimed

Dosing rates explicitly claimed

Dosage form and excipient classes

Scope implications for product design (freedom-to-operate style, claim-relevant)

A product is more likely to fall within claim 1 if it has all of:

• solid, non-aqueous tablet or gelatin capsule
• sodium phosphate salts in an amount effective for colonic purgation
• stomach dispersal mechanism
• optional but not required excipients limited to buffering/dispersal/binding categories

A product is less likely to map onto claim 9 if it:

• requires reconstitution and ingestion after dispersal into water prior to administration
• uses a different route or a different dosage form category than tablets/capsules (for method claim 11)

“Recipe steering” using dependent limitations

If a competitor’s formulation avoids the tight concentration envelopes used in claims 2-4 and 19, they may still face claim 1 exposure if their product still uses non-aqueous solid sodium phosphate salts effective for stomach dispersal colonic purgation. Dependent claims primarily add “backstop” species coverage; claim 1 remains the broad anchor.

US patent landscape: how to position 5,616,346 in the broader field

Landscape axis 1: sodium phosphate as a colon purgative

US 5,616,346 is part of a long-standing class of “saline/purgative” colon-cleansing actives centered on sodium phosphate salts. The novel emphasis in this patent is the dry non-aqueous solid architecture plus stomach dispersal and defined salt makeup ranges.

In practical landscape terms, this puts the patent in the intersection of:

• old therapeutic concept (sodium phosphate for bowel cleansing)
• formulation design (dry solid, non-aqueous, tablet/capsule)
• procedural administration constraint (“without dispersing into water prior to administration”)

Landscape axis 2: formulation technology around disintegration/dispersal

The patent’s “dispersal in the stomach” functional language plus excipient categories maps onto formulation strategies intended to get rapid gastric dispersion without pre-reconstitution.

This creates a typical competitive set:

• reformulated capsules/tablets with sodium phosphate
• excipient variations that improve or alter gastric dispersion time
• differing salt mixes (mono/di/tri) to tune osmolality or dissolution profile

Landscape axis 3: dosing and method variants

The method claims add quantified dosing windows (g/kg) for mono and di salts, and they allow variations like tribasic use and repeated administration steps. These claims typically become relevant for protocol-specific infringement arguments where a competitor adopts a matching dosing schedule.

Practical “claim coverage map” for enforcement and design-around

Most enforceable hook: claim 1

For a competitor product with:

• tablet/capsule
• non-aqueous dry formulation
• sodium phosphate salts effective for colonic purgation
• stomach dispersion behavior

claim 1 is the primary risk.

Secondary hooks: claims 2-5 and 19

If a competitor uses the exact mono/di concentration windows (or the ~70-73/26-30 split with 1-4% inert additives), the claim 19/2/3/4 coverage strengthens.

Method hook: claim 9

If a competitor’s patient instructions involve pre-dispersion in water prior to ingestion, that breaks the claim 9 “without dispersing” limitation. If the product is taken directly as a dry dosage form, method claim exposure increases.

Key Takeaways

• US 5,616,346 claims dry non-aqueous solid oral colonic purgative formulations using sodium phosphate salts designed to disperse in the stomach; dosage forms are tablets and gelatin capsules.
• Independent composition claim 1 is broad on salt identity (“at least one sodium phosphate salt”) and excipient categories (buffering/dispersal/binding), but it is anchored to the non-aqueous solid and stomach dispersal concept.
• Dependent claims create tight formulation embodiments: ~70-73 wt% monobasic and ~26-30 wt% dibasic, plus a defined ~1-4% inert additive concept in claim 19.
• Independent method claim 9 adds a procedural requirement: administer “without dispersing… into water prior to administration,” which can be a key design-around if a competitor uses pre-dispersion instructions.
• The patent landscape placement is best understood as formulation and administration differentiation within a longstanding sodium-phosphate bowel-cleansing therapeutic space, rather than a first-in-class therapeutic claim.

FAQs

1) Is US 5,616,346 limited to monobasic and dibasic sodium phosphate only?

No. Claim 1 covers at least one sodium phosphate salt, and dependent claims expressly include mono, di, and mixtures including tribasic.

2) What dosage forms are covered by the composition claims?

Tablets and gelatin capsules.

3) Does the patent require the composition to be administered without pre-dispersing into water?

That limitation appears in method claim 9 (“without dispersing said dry dosage form into water prior to administration”). Composition claim 1 is centered on the non-aqueous solid composition, not on patient pre-dispersion steps.

4) Where are the tightest formulation concentration ranges?

Claims 2-4 and claim 19, which define specific weight percentages for monobasic and dibasic sodium phosphate, and claim 19 also specifies 1-4% inert additives.

5) What excipient categories are contemplated by the patent?

Buffering agents, dispersal agents, and binding agents; buffering agent examples vary across dependent claims and include both inorganic salts and common excipient materials.

References

[1] US Patent No. 5,616,346. “Oral compositions for inducing purgation of the colon.”